Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy

Author:

Zhou Yutong1ORCID,Zhu Feiyan2ORCID,Liu Yang23ORCID,Zheng Meng2ORCID,Wang Yibin2ORCID,Zhang Dongya2ORCID,Anraku Yasutaka4,Zou Yan25,Li Jia3ORCID,Wu Haigang2ORCID,Pang Xiaobin3,Tao Wei6ORCID,Shimoni Olga7ORCID,Bush Ashley I.8ORCID,Xue Xue1ORCID,Shi Bingyang25ORCID

Affiliation:

1. State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300350, China.

2. Henan-Macquarie Uni Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, Henan 475004, China.

3. School of Pharmacy, Henan University, Kaifeng, Henan 475004, China.

4. Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.

5. Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.

6. Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

7. Institute for Biomedical Materials & Devices (IBMD), School of Mathematical and Physical Sciences, University of Technology Sydney, 15 Broadway, Ultimo, NSW 2007, Australia.

8. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.

Abstract

Glycosylated “triple-interaction” stabilized siRNA nanomedicine ameliorated AD neuropathology by targeting BACE1.

Funder

National Natural Science Foundation of China

National Key Technologies R&D Program of China

the Key Research Program in Colleges and Universities of Henan Province

Australian Endeavour Fellowship

Mason Foundation National Medical Program

National Health and Medical Research Council (NHMRC) Dementia Fellowship

National Health and Medical Research Council (NHMRC) Project Grant

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference52 articles.

1. Dementia prevention, intervention, and care

2. Alzheimer’s Disease International World Alzheimer Report 2019 (Alzheimer’s Disease International 2019) pp. 1–166.

3. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer’s disease and vascular dementia;Versijpt J.;J. Alzheimers Dis.,2014

4. Progress in Alzheimer’s disease drug discovery: An update;Williams M.;Curr. Opin. Investig. Drugs,2009

5. Drug treatments in Alzheimer’s disease;Briggs R.;Clin. Med.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3